Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you all for your patience. The conference call titled Amneal Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Call will begin shortly. During the presentation, you'll have the opportunity to ask a question by pressing star followed by the number one on your telephone keypads. Again, please stand by and we will begin in a few minutes. Thank you. Thank you. Good morning, and welcome to the Amniel Pharmaceuticals fourth quarter and full year 2025 earnings call. I'll now hand the call over to Amniel's head of investor relations, Tony DiMeo. Go ahead, please, sir. Good morning, and thank you for joining Amniel Pharmaceuticals fourth quarter 2025 earnings call. Today, we issued a press release reporting Q4 results. The earnings press release and presentation are available at amniel.com. Certain statements made on this call regarding matters that are not historical flags, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discussed non-GAAP measures, information on use of these measures and reconciliations to GAAP, are in the earnings release and presentation. On the call today are Chirag and Shintu Patel, co-founders and co-CEOs. Tasos Konideras, CFO. Our commercial leaders, Andy Boyer for Affordable Medicines, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag. Thank you, Tony, and good morning, everyone. 2025 was a defining year of excellent execution and portfolio expansion at MU. As a diversified biopharmaceutical company, across specialty, complex product...